Novel Fuzzy-based Framework for Ethical Innovation in COVID-19 Vaccine Production: Integrating Individual Organizational and Social Ethics

Subject Areas : Fuzzy Optimization and Modeling Journal

Shabnam Heydarkhani ¹ , Abbas Khamseh ² , Maryam Kheradranjbar ³

1 - Business Management Department, Islamic Azad University, Karaj Branch, Karaj, Iran
2 - Department of Industrial Management, Karaj Branch, Islamic Azad University, Karaj, Iran
3 - Department of Technology Management, Science and Research Branch, Islamic Azad University, Tehran, Iran

Received: 2024-10-04 Accepted : 2024-12-25 Published : 2024-04-24

Keywords: Organizational and Individual Ethics, Supervisory and Legal Ethics, Social Ethics, Infrastructures, Ethical Innovation, COVID-19 Vaccine Production ,

Abstract :

While several studies have addressed technical aspects of vaccine production, a comprehensive ethical framework that integrates individual, organizational, and social dimensions is still missing. This study presents a novel integrated ethical innovation model for human vaccines production, combining fuzzy-based methodology with structural equation modeling to capture both expert knowledge and empirical validation. This research is applied in terms of its purpose and quantitative-qualitative [mixed] in terms of its method. The statistical population consisted of the Razi Vaccine and Serum Research Institute and Pasteur Institute of Iran, both active in the vaccine production domain. The participants in the qualitative phase involved the vaccine production researchers and experts selected by snowball sampling till theoretical saturation was reached. The statistical sample in the quantitative phase included the managers and experts of the vaccine production domain and was selected by purposive and convenient sampling. The Fuzzy Delphi method run in the EXCEL software was used for extracting the variables and presenting the theoretical model, while the structural equations modeling run in the SMART PLS software was employed for factor analysis. The analysis gave rise to 60 initial indices, which were reduced to 53 after screening and Fuzzy Delphi analysis. Then, they were framed into five dimensions, including individual ethics, organizational ethics, supervisory and legal ethics, social ethics, and infrastructures. All identified factors significantly impact ethical innovation in the production of COVID-19 vaccine in the following order: Organizational ethics, supervisory and legal ethics, infrastructures, individual ethics, and social ethics.

References:

1. Agampodi, S., Mogeni, O. D., Chandler, R., Pansuriya, M., Kim, J. H., & Excler, J. L. (2024). Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution. Expert Review of Vaccines, 23(1), 761-772.
2. Akter, S., Fosso Wamba, S., & Dewan, S. (2017). Why PLS-SEM is suitable for complex modelling an empirical illustration in big data analytics quality. Production Planning & Control, 28(11-12), 1011-1021.
3. Alasti, K. (2019). Responsible Research and Innovation and the Concept of Moral Responsibility. Methodology of Social Sciences and Humanities, 25(100), 59-80
4. Anshari, M., Hamdan, M., Ahmad, N., Ali, E., & Haidi, H. (2023). COVID-19, artificial intelligence, ethical challenges and policy implications. AI & society, 38(2), 707-720.
5. Bell, B. P., Romero, J. R., & Lee, G. M. (2020). Scientific and ethical principles underlying recommendations from the advisory committee on immunization practices for COVID-19 vaccination implementation. Jama, 324(20), 2025-2026.
6. Binagwaho, A., Mathewos, K., & Davis, S. (2021). Time for the ethical management of COVID-19 vaccines. The Lancet Global Health, 9(8), 1169-1171.
7. Boschiero, N. (2022). COVID-19 vaccines as global common goods: An integrated approach of ethical, economic policy and intellectual property management. Global Jurist, 22(2), 177-230.
8. Centers for Disease Control and Prevention. (2017). Public Health Law Program. State school and childcare vaccination laws. Atlanta (GA): Centers for Disease Control and Prevention.
9. Chawana, R., Mamabolo, A., & Apostoleris, E. (2024). The influence of institutional logics on vaccine development, production and distribution in Africa. International Journal of Operations & Production Management, 111-120.
10. Dhai, A. (2023). Equitable Access to COVID-19 Vaccines, Vaccine Research, and Vaccine Apartheid on the African Continent: Challenges and Recommendations. In Ethical innovation for global health: Pandemic, democracy and ethics in research (pp. 39-55). Singapore: Springer Nature Singapore.
11. Diller, E. R., & Williamson, L. (2023). Supporting One Health for pandemic prevention: The need for ethical innovation. Journal of Bioethical Inquiry, 20(3), 345-352.
12. Fornell, C., & Larcker, D. F. (1981). Evaluating structural equation models with unobservable variables and measurement error. Journal of marketing research, 18(1), 39-50.
13. Gholamzadeh, R., Azar, A., & Ghanavati, M. (2012). Route-Structural Modeling in Management: Application of Smart PLS Software. Negahe Danesh.(in Persian).
14. Hair, J. F., Ringle, C. M., & Sarstedt, M. (2011). PLS-SEM: Indeed, a silver bullet. Journal of Marketing theory and Practice, 19(2), 139-152.
15. Iserson, K. V. (2021). SARS-CoV-2 (COVID-19) vaccine development and production: an ethical way forward. Cambridge Quarterly of Healthcare Ethics, 30(1), 59-68.
16. Ishikawa, A., Amagasa, M., Shiga, T., Tomizawa, G., Tatsuta, R., & Mieno, H. (1993). The max-min Delphi method and fuzzy Delphi method via fuzzy integration. Fuzzy sets and systems, 55(3), 241-253.
17. Jecker, N. S., Wightman, A. G., & Diekema, D. S. (2021). Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines. Journal of Medical Ethics, 47(5), 308-317.
18. Keeney, S., Hasson, F., & McKenna, H. P. (2001). A critical review of the Delphi technique as a research methodology for nursing. International journal of nursing studies, 38(2), 195-200.
19. Law, E., & Smith, I. (2024). Ethical and informative trials: How the COVID-19 experience can help to improve clinical trial design. Research Ethics, 20(4), 764-779.
20. Legel, D. (2016). The tension between individual and collective interests in capital-forming life insurance: a consideration with particular reference to the current case law of the Federal Court of Justice. Optimus-Verlag, 221-231.
21. Marandi, V., Tabatabaeian, S. H., Jafari, P., & Azarnoosh, M. (2017). An analysis on technological innovation system regarding Iranian bio-products (focused on human vaccines). Innovation Management Journal, 6(3), 1-26.
22. Marciano, C. (2024). The social shaping of biotechnological innovation. The case of Covid-19 protein vaccine in Cuba and the US. BioSocieties, 1-29.
23. Nasri, S., Fatemi, M., Nazeri, N., & Ghazinoory, S. (2024). The new framework of innovation biosphere for analysing innovation policies facing COVID-19 grand challenge. Health Research Policy and Systems, 22(1), 69-75.
24. Privor-Dumm, L., Excler, J. L., Gilbert, S., Karim, S. S. A., Hotez, P. J., Thompson, D., & Kim, J. H. (2023). Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Global Health, 8(6), 118-121.
25. Reijers, W., Wright, D., Brey, P., Weber, K., Rodrigues, R., O’Sullivan, D., & Gordijn, B. (2018). Methods for practising ethics in research and innovation: A literature review, critical analysis and recommendations. Science and Engineering Ethics, 24, 1437-1481.
26. Rhodes, P., & Parry, P. (2024). Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context. Pathology Research and Practice, 253, 155030.
27. Scholz, M., Smith, N. C., Riegler, M., & Burton, A. (2024). Public health and political corporate social responsibility: Pharmaceutical company engagement in COVAX. Business & Society, 63(4), 813-850.
28. Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N. M. & Pollock, K. M. (2020). Vaccines for COVID-19. Clinical & Experimental Immunology, 202(2), 162-192.
29. US Department of Health and Human Services. (2015). Special protections for children as research subjects.
30. Vuong, Q. H., Le, T. T., La, V. P., Nguyen, H. T. T., Ho, M. T., Van Khuc, Q., & Nguyen, M. H. (2022). Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. Humanities and Social Sciences Communications, 9(1), 421-430.
31. Yuan, X., & Li, X. (2022). Pledging patent rights for fighting against the COVID-19: from the ethical and efficiency perspective. Journal of Business Ethics, 179(3), 683-696.
32. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J. & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727-733.